tbuckley/cabot-search huggingface dataset:
The predictors of information needs and different views of patients and relatives on disclosure and treatment participation: A multicentric survey study
Authors: M. Ozdogan, H. Bozcuk, O. Er, H. Abali, H. S. Coskun, N. Zengin, M. Artac, B. Savas
Journal: Journal of Clinical Oncology (2009)

e20526 Background: We wanted to explain if the views of patients and their relatives differed on disclosure and treatment participation or not, and if so, to evaluate the predictors of this difference. Methods: The survey aimed to unveil the attitude of patients and their relatives in 3 domains; disclosure of diagnosis, prognosis and participation to treatment. Multinomial logistic regression models with forward selection procedure were constructed for the multivariate analysis to explain the origins of discordance in these domains. Results: A total of 1,052 consecutive cases (526 patients and their 526 relatives) were interviewed. The relatives, when they were asked to imagine themselves with a new diagnosis of cancer, opted for disclosure of diagnosis, prognosis, and participation to treatment in 92.4%, 84.6%, and 86.3% of cases. When patients were asked for their information needs in disclosure of diagnosis, prognosis, and participation to treatment, 83.8%, 70.2%, and 70% wanted disclosure, whereas, their relatives wanted disclosure for their patients in these 3 domains in 32.9%, 40.5%, and 60.3% of cases, respectively. The multivariate predictors of discordance for disclosure of diagnosis between patients and relatives were patient age, social insurance, and oncology centers (P=0.003, 0.007, and &lt;0.001, respectively). The associates of discordance for disclosure of prognosis were again oncology centers and relatives’ relationship with the patients (P&lt;0.001 and 0.012). Likewise, the correlates of discordance for treatment participation were again oncology centers and patient age (P&lt;0.001 and 0.016). Conclusions: Information needs of patients and their relatives, when they imagine themselves as cancer patients, are quite similar. However, relatives are not in favor of disclosure to their patients of diagnosis and prognosis, moreover, in spite of this, they want their patients to actively participate in treatment decisions. We believe this paradox represents a desire of the relatives to escape from responsibility and emotional burden of the care of the cancer patients. This paradox, in addition, is a threat to a healthy patient and physician communication. No significant financial relationships to disclose.
Breast Cancer Risk After Ovarian Stimulation for In Vitro Fertilization—Reply
Authors: Alexandra W. van den Belt-Dusebout, Flora E. van Leeuwen, Curt W. Burger
Journal: JAMA (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Chronic Lymphocytic Leukemia (CLL) in Parents and Children.
Authors: Francesca R. Mauro, Emanuela M. Ghia, Maria S. De Propris, Elena Giammartini, Irene Della Starza, Diana Giannarelli, Ilaria Del Giudice, Simona Santangelo, Fulvia Brugnoletti, Massimo Gentile, Anna Guarini, Robert Foa
Journal: Blood (2006)
GW26-e1318 Association of the 11-β hydroxysteroid dehydrogenase G534A gene polymorphism with essential hypertension: a meta-analysis
Authors: Jinghui Zheng, Xiaocong Ma, Tiehua Wang, Mei Zhao, Mingdong Xu, Jianxiang Li, Xueqiu Deng, Guihua Yue
Journal: Journal of the American College of Cardiology (2015)
Serologic Response to Meningococcal Vaccination in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) for the Chronic Treatment with the Terminal Complement Inhibitor Eculizumab
Authors: Alexander Roeth, Ferras Alashkar, Doerte Herich-Terhuerne, Johannes Elias, Ulrich Vogel, Ulrich Duehrsen
Journal: Blood (2014)
Micrometastasis in sentinel (SLN) and non-sentinel lymph nodes of breast cancer: An update including clinico-pathologic impact and survival
Authors: G. Masci, L. Di Tommaso, I. Del Prato, S. E. Orefice, G. Gullo, A. Rubino, M. W. Eboli, E. Morenghi, M. Roncalli, A. Santoro
Journal: Journal of Clinical Oncology (2006)

10602 Aims: To assess the rate of positive axillary clearance when the SLN biopsy contains micro-metastatic disease and to evaluate the survival impact of local lymph nodes with micro-metastases. Materials and Methods: From 1997 to 2005 2,750 consecutive patients (pts) underwent breast surgery with SLN biopsy or axillary dissection. Of these, 87 pts had lymph node micro-metastases assessed with haematoxylin and eosin or cytokeratine staining and defined according to the current TNM classification. Lymph node micro-metastases were found after axillary dissection in 27 pts and after SLN biopsy in 60 cases; 55 (63.2%) were micro-metastases 0.2–1 mm, 22 (25.3%) measured 1–2 mm, 7 were isolated tumor cells and in 3 cases size was not available; micro-metastases were located within lymph node sinuses in 43 and in nodal parenchyma in 37 cases. Age: median 53 years (range 34–78), surgery: 77 (88.5%) conservative and 10 radical mastectomy; histotype: 79 (90.8%) ductal, 4 lobular, 2 tubular and 2 other histotypes. T stage: pT1a/pT1b in 16 (18.4%), pT1c in 54 (62.1%) and pT2 in 17 (19.5%) pts; grading 3 in 24 pts (27.6%); 76 pts (87.3%) had positive Er/Pgr; vascular invasion: present in 30 pts (34.5%); HER-2/neu overexpression in 16 (18.4%) pts; 64 pts (73.6%) received adjuvant chemotherapy (49 AC, 11 CMF ev, and 4 FEC); 69 pts (79.3%) had radiotherapy and hormonal therapy. Results: Among 60 pts with SLN micro-metastases, 8 (13%) had further axillary involvement; in 5/8 cases size of micro-metastases was &gt;1 mm, in 7/8 cases micro-metastases were located in the nodal parenchyma. These 8 pts were not considered for survival analysis. Of the remaining 79 patients with micro-metastases, survival data were as follow: at median follow-up time of 32 months (range 2–158) 69 pts were alive without any evidence of disease, 4 pts died of disease and 6 pts were alive with disease. Three years DFS was 87.75% and OS 95.57%. Conclusions: Further axillary involvement was found in 13% of pts with micrometastases in the SLN biopsy supporting complete nodal dissection in all pts.Our preliminary results show that even minimal nodal involvement could correlate to worse prognosis and may require adjuvant treatment. No significant financial relationships to disclose.
Characterization of Long-Term Survivors and a Predictive Model for Aggressive Adult T-Cell Leukemia-Lymphoma (ATL): An Ancillary Study by the Japan Clinical Oncology Group, JCOG0902A
Authors: Takuya Fukushima, Shogo Nomura, Masanori Shimoyama, Atae Utsunomiya, Taro Shibata, Kenji Ishitsuka, Yukiyoshi Moriuchi, Shinichiro Yoshida, Naokuni Uike, Hiroyuki Hata, Fumio Kawano, Eisaburo Sueoka, Kimiharu Uozumi, Masato Masuda, Yasuaki Yamada, Harumi Kaba, Yuko Watanabe, Haruhiko Fukuda, Tomomitsu Hotta, Kensei Tobinai, Kunihiro Tsukasaki
Journal: Blood (2011)
Dietary Factors and Amyotrophic Lateral Sclerosis
Authors: Michael Swash
Journal: JAMA Neurology (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Neurology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Neurology journal
Cross‐sectional study on allergic sensitization of Austrian adolescents using molecule‐based IgE profiling
Authors: T. Stemeseder, E. Klinglmayr, S. Moser, L. Lueftenegger, R. Lang, M. Himly, G. J. Oostingh, J. Zumbach, A. C. Bathke, T. Hawranek, G. Gadermaier
Journal: Allergy (2016)

Allergen-specific IgE antibodies are a hallmark of type I allergy. The aim of this cross-sectional study was to analyze the sensitization profiles of an Austrian adolescent population utilizing molecule-based IgE diagnosis.Serum samples of 501 nonselected pupils from Salzburg, Austria, were tested in ImmunoCAP ISAC® for IgE reactivity to 112 single allergens. Sensitization profiles were assessed and statistically coordinated with reported allergies.In the population aged 12-21 years, 53.5% showed IgE reactivity to at least one allergen tested. The highest prevalence was found for Phl p 1 from grass pollen (26.5%), group 2 mite allergens (18.2%), Bet v 1 from birch pollen (16.3%) and Fel d 1 from cat (14.4%). The majority of participants showed a complex sensitization profile and reacted on average to 9 allergens. Pollen sensitization was highly prevalent (41.7%) and mainly driven by group I grass and PR-10 allergens of the Betulaceae family, while Pla l 1 represented the most relevant weed. Diagnosed and self-reported allergies were noted in 21.9% and 45.5% of participants, respectively, and correlated well with in vitro results. Among atopic individuals, 71.4% reported to suffer from at least one allergy; concordance was found for grass and cat sensitization, while venom- and weed pollen-positive individuals were frequently asymptomatic.More than half of the tested adolescent population had already established an atopic status presenting a complex IgE reactivity profile dominated by pollen sensitization. Detailed molecule-based analysis allows determining relevant biomarkers and monitoring of the atopic status in populations.
Advances in Imaging Brain Metabolism
Authors: Fahmeed Hyder, Douglas L. Rothman
Journal: Annual Review of Biomedical Engineering (2017)

Metabolism is central to neuroimaging because it can reveal pathways by which neuronal and glial cells use nutrients to fuel their growth and function. We focus on advanced magnetic resonance imaging (MRI) and magnetic resonance spectroscopy (MRS) methods used in brain metabolic studies. 17 O-MRS and 31 P-MRS, respectively, provide rates of oxygen use and ATP synthesis inside mitochondria, whereas 19 F-MRS enables measurement of cytosolic glucose metabolism. Calibrated functional MRI (fMRI), an advanced form of fMRI that uses contrast generated by deoxyhemoglobin, provides maps of oxygen use that track neuronal firing across brain regions. 13 C-MRS is the only noninvasive method of measuring both glutamatergic neurotransmission and cell-specific energetics with signaling and nonsignaling purposes. Novel MRI contrasts, arising from endogenous diamagnetic agents and exogenous paramagnetic agents, permit pH imaging of glioma. Overall, these magnetic resonance methods for imaging brain metabolism demonstrate translational potential to better understand brain disorders and guide diagnosis and treatment.
Abstract C35: Epigenetic repression of hexokinase 2 is responsible for the heterogeneity of 18F-FDG uptake in hepatocellular carcinoma
Authors: Kim Hyemi, Lee Hyun Gyu, Lee Jae Myun, Park Jeon Han
Journal: Cancer Research (2016)

Abstract The clinical usefulness of 18F-2-fluoro-2-deoxy-D-glucose (18F-FDG) positron emission tomography (PET), based on aerobic glycolysis, has been recently challenged in hepatocellular carcinoma (HCC) due to the heterogeneity of 18F-FDG uptake. Although inconsistent 18F-FDG uptake in HCCs is explained by the heterogeneous expression of hexokinase 2 (HK2), the underlying molecular mechanism remains elusive. Here, we examined the methylation status of the HK2 promoter and its influence on hypoxia-inducible factor-1α (HIF-1α) binding. We first confirmed inconsistent 18F-FDG uptake and correlative HK2 expression. Utilizing the HumanMethylation450 array, we discovered hypermethylation of the HK2 promoter CpG island (CGI) region in HK2negative HCCs. Studies using HK2 promoter luciferase constructs showed that a newly defined hypoxia responsive element (HRE) regulates HK2 expression. We also found that differential glucose uptake is caused by the differential HK2 expression due to differential methylation of the HK2 promoter CGI region in HCC cell lines. Finally, treatment with 5-Aza-2-deoxycytidine and hypoxic stimuli significantly increased HK2 expression due to increased HIF-1α binding to the HRE, resulting in increased glucose uptake in HK2negative SNU449 cells. Conclusion: These data indicate that methylation changes in the HK2 promoter CGI region in HCCs influence HK2 expression by regulating HIF-1α binding to the HRE in the CGI region. Hypermethylation of the HK2 promoter CGI region in HK2negative tissues inhibits the binding of HIF-1α to the HK2 promoter, resulting in the suppression of HK2 expression, which contributes to the heterogeneity of 18F-FDG uptake. Citation Format: Kim Hyemi, Lee Hyun Gyu, Lee Jae Myun, Park Jeon Han. Epigenetic repression of hexokinase 2 is responsible for the heterogeneity of 18F-FDG uptake in hepatocellular carcinoma. [abstract]. In: Proceedings of the AACR Special Conference: Function of Tumor Microenvironment in Cancer Progression; 2016 Jan 7–10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2016;76(15 Suppl):Abstract nr C35.
Differential Response to Hypomethylating Agents Based on Sex: A Report on Behalf of the MDS Clinical Research Consortium (MDS CRC)
Authors: Amy E. DeZern, Amer M. Zeidan, John Barnard, Wesley Hand, Najla Al Ali, Francis Brown, Cassie Zimmerman, Gail J Roboz, Rami S. Komrokji, Guillermo Garcia-Manero, David P. Steensma, Mikkael A. Sekeres
Journal: Blood (2015)
Proteasome Inhibitor Treatment in Multiple Myeloma Can Mobilize Hematopoietic Stem Cells in the Absence of G-CSF
Authors: John N. Allan, David Jayabalan, Ruben Niesvizky, Tomer M Mark, Roger Pearse, Adriana C Rossi, Linda Tegnestam, Duane C Hassane, Monica L. Guzman
Journal: Blood (2014)
GW26-e4468 Effect of Aconine on the expression of Caveolin-1 and eNOS in EAhy926 cell injured by Homocysteine
Authors: Yong Liu, Shujie Yu, Bin Zhou, Baoshun Hao, Min Wang, Dinghui Liu, Lin Wu, Zhiming Song, Ximei Zhang, Lin Chen, Xiaoxian Qian
Journal: Journal of the American College of Cardiology (2015)
Enhancer Landscape Dynamics and the Role of IRF8 in Mononuclear Phagocyte Development
Authors: Daisuke Kurotaki, Jun Nakabayashi, Akira Nishiyama, Haruka Sasaki, Naofumi Kaneko, Shin-ichi Koizumi, Keiko Ozato, Yutaka Suzuki, Tomohiko Tamura
Journal: Blood (2015)
Pattern of growth of retroperitoneal sarcoma: Do they push or infiltrate adjacent organs? Analysis of a single institution series.
Authors: C. E. Mussi, P. Bagnoli, M. Coladonato, A. Bertuzzi, S. Secondino, A. Santoro, P. Colombo, P. Navarria, E. Morenghi, V. Quagliuolo
Journal: Journal of Clinical Oncology (2010)

10086 Background: The mainstay of treatment for primary and recurrent retroperitoneal sarcoma (RPS) is surgery, but the best therapeutic approach is not established yet. We analyzed a large single-institution series of RPS with the aim of providing information useful to surgical decision-making. Methods: From 1996 to 2008, 150 patients referred to our Institution underwent surgery for RPS (77 primary tumors, 73 recurrent). Potential prognostic factors including histology, tumor grading, time to last recurrence and multifocality, were retrospectively tested by univariate and multivariate analysis. Primary end-points were local disease-free survival (LDFS) and overall survival (OS). In the subgroup of primary tumors, the number of resected organs, viscera invasion and surgical margins were also assessed. Results: 5-year LDFS and OS for the whole population were 28% and 79%, respectively. In the subgroup of primary patients, 5-year LDFS and OS were 52% and 73%, respectively. Twenty patients (13%) developed distant metastases (55% pulmonary; 65% extrapulmonary). Fifty primary tumors (64%) were treated by multivisceral associated resection (90% of leiomyosarcoma, 70% of liposarcoma and 40% of the other histologies). At pathologic examination, viscera infiltration was recorded in 40/50 cases (80%); eighteen of these were liposarcomas (11 well-differentiated, 7 dedifferentiated), 13 were leiomyosarcomas. The renal fat capsule was infiltrated in 19/24 (79%) cases; direct kidney infiltration (cortical or vascular structures) was observed in 10/24 (42%) cases. Microscopic positive margins were recorded in 19/77 (25%) cases. Sex, histology and tumor grading have been identified as independent prognostic factors for LDFS. Sex and grading predicted OS. Conclusions: This series, where an aggressive surgical policy has been adopted along with extensive pathologic sampling, shows that RPS not only push the adjacent organs, but have also a high rate of visceral infiltration. This growth pattern is characteristic not only of high grade RPS, but also of well differentiated liposarcoma. These pathologic data should be considered when the surgical strategy is planned. No significant financial relationships to disclose.
Abstract A11: Targeting vascular endothelial growth factor in myeloid cells enhances natural killer cell responses to chemotherapy and ameliorates cachexia
Authors: Magali Castells, Ralph Klose, Dagmar Gotthardt, Eva-Maria Putz, Ewelina Krzywinska, Chahrazade Kantari-Mimoun, Naima Chikdene, Anna-Katharina Meinecke, Katrin Schroedter, Iris Helfrich, Joachim Fandrey, Veronika Sexl, Christian Stockmann
Journal: Cancer Research (2016)

Abstract Chemotherapy remains a mainstay of cancer treatment but its use is often limited by the development of adverse reactions. Severe involuntary loss of body weight (cachexia) is a frequent cause of death in cancer patients and is exacerbated by chemotherapy. We show that, in contrast to antibody-mediated neutralization of Vascular Endothelial Growth Factor (VEGF)-A, genetic inactivation of VEGF-A in tumor-associated myeloid cells prevents chemotherapy-induced cachexia by inhibiting skeletal muscle loss and the lipolysis of white adipose tissue. It also improves clearance of senescent tumor cells by natural killer cells and inhibits tumor regrowth after chemotherapy. The effects depend on the adipokine and chemoattractant chemerin, which is released by the tumur endothelium in response to chemotherapy. The findings define chemerin as a critical mediator of the immune response elicited by chemotherapy as well as an important inhibitor of cancer cachexia. Efficient targeting of VEGF signaling within the tumor microenvironment should impede weight loss that is frequently associated with chemotherapy, thereby dramatically improving the therapeutic outcome. Citation Format: Magali Castells, Ralph Klose, Dagmar Gotthardt, Eva-Maria Putz, Ewelina Krzywinska, Chahrazade Kantari-Mimoun, Naima Chikdene, Anna-Katharina Meinecke, Katrin Schroedter, Iris Helfrich, Joachim Fandrey, Veronika Sexl, Christian Stockmann. Targeting vascular endothelial growth factor in myeloid cells enhances natural killer cell responses to chemotherapy and ameliorates cachexia. [abstract]. In: Proceedings of the AACR Special Conference: Function of Tumor Microenvironment in Cancer Progression; 2016 Jan 7–10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2016;76(15 Suppl):Abstract nr A11.
A Phase III Study of Double Autotransplantation Incorporating Bortezomib-Thalidomide-Dexamethasone (VTD) or Thalidomide-Dexamethasone (TD) for Multiple Myeloma: Superior Clinical Outcomes with VTD Compared to TD.
Authors: Michele Cavo, Paola Tacchetti, Francesca Patriarca, Maria Teresa Petrucci, Lucia Pantani, Monica Galli, Francesco Di Raimondo, Claudia Crippa, Sara Bringhen, Massimo Offidani, Franco Narni, Vittorio Montefusco, Elena Zamagni, Tonino Spadano, Norbert Pescosta, Luca Baldini, Claudia Cellini, Tommaso Caravita, Antonio Ledda, Antonietta Falcone, Patrizia Tosi, Chiara Nozzoli, Renato Zambello, Luciano Masini, Paola Agostini, Mauro Fiacchini, Michele Baccarani
Journal: Blood (2009)
Nucleolin Targeting Impairs the Progression of Pancreatic Cancer and Promotes the Normalization of Tumor Vasculature
Authors: Maud-Emmanuelle Gilles, Federica Maione, Mélissande Cossutta, Gilles Carpentier, Laure Caruana, Silvia Di Maria, Claire Houppe, Damien Destouches, Ksenya Shchors, Christopher Prochasson, Fabien Mongelard, Simona Lamba, Alberto Bardelli, Philippe Bouvet, Anne Couvelard, José Courty, Enrico Giraudo, Ilaria Cascone
Journal: Cancer Research (2016)

Abstract Pancreatic cancer is a highly aggressive tumor, mostly resistant to the standard treatments. Nucleolin is overexpressed in cancers and its inhibition impairs tumor growth. Herein, we showed that nucleolin was overexpressed in human specimens of pancreatic ductal adenocarcinoma (PDAC) and that the overall survival significantly increased in patients with low levels of nucleolin. The nucleolin antagonist N6L strongly impaired the growth of primary tumors and liver metastasis in an orthotopic mouse model of PDAC (mPDAC). Similar antitumor effect of N6L has been observed in a highly angiogenic mouse model of pancreatic neuroendocrine tumor RIP-Tag2. N6L significantly inhibited both human and mouse pancreatic cell proliferation and invasion. Notably, the analysis of tumor vasculature revealed a strong increase of pericyte coverage and vessel perfusion both in mPDAC and RIP-Tag2 tumors, in parallel to an inhibition of tumor hypoxia. Nucleolin inhibition directly affected endothelial cell (EC) activation and changed a proangiogenic signature. Among the vascular activators, nucleolin inhibition significantly decreased angiopoietin-2 (Ang-2) secretion and expression in ECs, in the tumor and in the plasma of mPDAC mice. As a consequence of the observed N6L-induced tumor vessel normalization, pre-treatment with N6L efficiently improved chemotherapeutic drug delivery and increased the antitumor properties of gemcitabine in PDAC mice. In conclusion, nucleolin inhibition is a new anti-pancreatic cancer therapeutic strategy that dually blocks tumor progression and normalizes tumor vasculature, improving the delivery and efficacy of chemotherapeutic drugs. Moreover, we unveiled Ang-2 as a potential target and suitable response biomarker for N6L treatment in pancreatic cancer. Cancer Res; 76(24); 7181–93. ©2016 AACR.
GW26-e5438 Cystatin C- Versus Creatinine-Based Definition of Renal Dysfunction for Predicting Poor Coronary Collateralization in Type 2 Diabetic Patients with Stable Coronary Artery Disease
Authors: Ying Shen, Fenghua Ding, Ruiyan Zhang, Qi Zhang, Lin Lu, Weifeng Shen
Journal: Journal of the American College of Cardiology (2015)